Eye drug safety: the impact of a Cochrane Review comparing two treatments for macular degeneration

Cochrane evidence helping to change treatment policies and decisions

For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.

The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important consideration given that bevacizumab is considerably less expensive than ranibizumab.

Since then this Cochrane Review has had a significant impact. Author Lorenzo Moja, based at the University of Milan, tells the story so far…

Friday, July 1, 2016
Share/Save